Which has stronger earnings and valuation, ANVS or ALXO?

ALX Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.79 N/A ALX Oncology N/A N/A -$101.69M -$1.13 N/A

Is ANVS or ALXO more profitable?

ALX Oncology's return on equity of -90.30% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -685.98% -258.77% ALX Oncology N/A -90.30% -67.28%

Does the media refer more to ANVS or ALXO?

In the previous week, ALX Oncology had 9 more articles in the media than Annovis Bio. MarketBeat recorded 13 mentions for ALX Oncology and 4 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.62 beat ALX Oncology's score of 0.06 indicating that Annovis Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IVVD or ANVS more profitable?

Annovis Bio has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -183.90% -59.73% -48.97% Annovis Bio N/A -685.98% -258.77%

Does the media favor IVVD or ANVS?

In the previous week, Invivyd had 27 more articles in the media than Annovis Bio. MarketBeat recorded 31 mentions for Invivyd and 4 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.62 beat Invivyd's score of 0.24 indicating that Annovis Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ARCT or ANVS?

In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 4 articles in the media. Arcturus Therapeutics' average media sentiment score of 0.97 beat Annovis Bio's score of 0.62 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALEC or ANVS more profitable?

Annovis Bio has a net margin of 0.00% compared to Alector's net margin of -850.13%. Alector's return on equity of -531.03% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Alector -850.13% -531.03% -44.00% Annovis Bio N/A -685.98% -258.77%

Does the media prefer ALEC or ANVS?

In the previous week, Annovis Bio had 3 more articles in the media than Alector. MarketBeat recorded 4 mentions for Annovis Bio and 1 mentions for Alector. Alector's average media sentiment score of 1.67 beat Annovis Bio's score of 0.62 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EBS or ANVS?

In the previous week, Emergent Biosolutions had 2 more articles in the media than Annovis Bio. MarketBeat recorded 6 mentions for Emergent Biosolutions and 4 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.62 beat Emergent Biosolutions' score of 0.11 indicating that Annovis Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Emergent Biosolutions 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Annovis Bio (ANVS) Competitors

$1.81 +0.02 (+1.12%)

As of 08/21/2026 03:58 PM Eastern

Compare

ANVS vs. ALXO, IVVD, ARCT, ALEC, and EBS

Should you buy Annovis Bio stock or one of its competitors? Annovis Bio's main competitors and comparable companies include ALX Oncology (ALXO), Invivyd (IVVD), Arcturus Therapeutics (ARCT), Alector (ALEC), and Emergent Biosolutions (EBS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Annovis Bio compare to ALX Oncology?

Annovis Bio (NYSE:ANVS) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

In the previous week, ALX Oncology had 9 more articles in the media than Annovis Bio. MarketBeat recorded 13 mentions for ALX Oncology and 4 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.62 beat ALX Oncology's score of 0.06 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 12.4% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ALX Oncology is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

Annovis Bio has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

ALX Oncology's return on equity of -90.30% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
ALX Oncology	N/A	-90.30%	-67.28%

Annovis Bio currently has a consensus price target of $11.67, indicating a potential upside of 544.57%. ALX Oncology has a consensus price target of $4.60, indicating a potential upside of 125.49%. Given Annovis Bio's higher probable upside, research analysts clearly believe Annovis Bio is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Annovis Bio and ALX Oncology tied by winning 7 of the 14 factors compared between the two stocks.

How does Annovis Bio compare to Invivyd?

Invivyd (NASDAQ:IVVD) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Invivyd has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

Annovis Bio has lower revenue, but higher earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	5.50	-$52.49M	-$0.33	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

Invivyd presently has a consensus price target of $8.00, suggesting a potential upside of 702.81%. Annovis Bio has a consensus price target of $11.67, suggesting a potential upside of 544.57%. Given Invivyd's higher possible upside, research analysts plainly believe Invivyd is more favorable than Annovis Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Invivyd had 27 more articles in the media than Annovis Bio. MarketBeat recorded 31 mentions for Invivyd and 4 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.62 beat Invivyd's score of 0.24 indicating that Annovis Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 12.3% of Invivyd shares are owned by insiders. Comparatively, 20.8% of Annovis Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Annovis Bio has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
Annovis Bio	N/A	-685.98%	-258.77%

Summary

Invivyd and Annovis Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Annovis Bio compare to Arcturus Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

In the previous week, Arcturus Therapeutics and Arcturus Therapeutics both had 4 articles in the media. Arcturus Therapeutics' average media sentiment score of 0.97 beat Annovis Bio's score of 0.62 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annovis Bio has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
Annovis Bio	N/A	-685.98%	-258.77%

Arcturus Therapeutics currently has a consensus price target of $20.00, indicating a potential upside of 48.70%. Annovis Bio has a consensus price target of $11.67, indicating a potential upside of 544.57%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Arcturus Therapeutics has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market.

94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 20.8% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Annovis Bio has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	4.66	-$65.78M	-$3.31	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

Summary

Arcturus Therapeutics beats Annovis Bio on 7 of the 13 factors compared between the two stocks.

How does Annovis Bio compare to Alector?

Alector (NASDAQ:ALEC) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Annovis Bio has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	12.52	-$142.93M	-$1.10	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

In the previous week, Annovis Bio had 3 more articles in the media than Alector. MarketBeat recorded 4 mentions for Annovis Bio and 1 mentions for Alector. Alector's average media sentiment score of 1.67 beat Annovis Bio's score of 0.62 indicating that Alector is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alector has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market.

Annovis Bio has a net margin of 0.00% compared to Alector's net margin of -850.13%. Alector's return on equity of -531.03% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
Annovis Bio	N/A	-685.98%	-258.77%

85.8% of Alector shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alector currently has a consensus price target of $3.63, indicating a potential upside of 53.60%. Annovis Bio has a consensus price target of $11.67, indicating a potential upside of 544.57%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Annovis Bio beats Alector on 9 of the 16 factors compared between the two stocks.

How does Annovis Bio compare to Emergent Biosolutions?

Emergent Biosolutions (NYSE:EBS) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Emergent Biosolutions currently has a consensus target price of $10.00, indicating a potential upside of 97.24%. Annovis Bio has a consensus target price of $11.67, indicating a potential upside of 544.57%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than Emergent Biosolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Emergent Biosolutions has higher revenue and earnings than Annovis Bio. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.90M	0.35	$52.60M	-$3.55	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

In the previous week, Emergent Biosolutions had 2 more articles in the media than Annovis Bio. MarketBeat recorded 6 mentions for Emergent Biosolutions and 4 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.62 beat Emergent Biosolutions' score of 0.11 indicating that Annovis Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Emergent Biosolutions	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Emergent Biosolutions has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market.

Annovis Bio has a net margin of 0.00% compared to Emergent Biosolutions' net margin of -22.95%. Emergent Biosolutions' return on equity of 16.35% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-22.95%	16.35%	6.17%
Annovis Bio	N/A	-685.98%	-258.77%

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 6.0% of Emergent Biosolutions shares are owned by insiders. Comparatively, 20.8% of Annovis Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Emergent Biosolutions and Annovis Bio tied by winning 8 of the 16 factors compared between the two stocks.

Get Annovis Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANVS vs. The Competition

Export

Metric	Annovis Bio	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$77.54M	$4.01B	$7.37B	$24.30B
Dividend Yield	N/A	3.64%	2.53%	3.70%
P/E Ratio	-1.01	11.62	272.60	30.31
Price / Sales	N/A	1,338.17	618.96	19.89
Price / Cash	N/A	105.14	78.62	32.49
Price / Book	-18.10	16.80	13.05	6.77
Net Income	-$28.85M	-$12.50M	$3.47B	$1.07B
7 Day Performance	-1.90%	3.29%	2.09%	-0.65%
1 Month Performance	3.72%	8.23%	6.64%	3.38%
1 Year Performance	-24.01%	55.05%	25.02%	14.90%

Annovis Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANVS Annovis Bio	3.171 of 5 stars	$1.81 +1.1%	$11.67 +544.6%	-24.0%	$77.54M	N/A	N/A	3	News Coverage Earnings Report Analyst Forecast
ALXO ALX Oncology	1.7659 of 5 stars	$2.05 +3.8%	$4.60 +124.9%	+74.4%	$284.16M	N/A	N/A	40	Trending News Analyst Upgrade Analyst Revision
IVVD Invivyd	3.1943 of 5 stars	$0.84 +12.9%	$8.00 +856.9%	+91.6%	$242.46M	$53.43M	N/A	100	News Coverage Analyst Forecast Analyst Revision
ARCT Arcturus Therapeutics	1.9035 of 5 stars	$8.42 +3.4%	$24.25 +188.1%	-27.3%	$239.89M	$82.03M	N/A	180	News Coverage
ALEC Alector	2.3565 of 5 stars	$2.14 +4.2%	$3.63 +69.7%	-6.3%	$239.50M	$13.86M	N/A	270	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANVS) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, IVVD, ARCT, ALEC, and EBS

How does Annovis Bio compare to ALX Oncology?

Summary

How does Annovis Bio compare to Invivyd?

Summary

How does Annovis Bio compare to Arcturus Therapeutics?

Summary

How does Annovis Bio compare to Alector?

Summary

How does Annovis Bio compare to Emergent Biosolutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, IVVD, ARCT, ALEC, and EBS

How does Annovis Bio compare to ALX Oncology?

Does the media refer more to ANVS or ALXO?

Do institutionals & insiders believe in ANVS or ALXO?

Which has stronger earnings and valuation, ANVS or ALXO?

Which has more volatility and risk, ANVS or ALXO?

Is ANVS or ALXO more profitable?

Do analysts rate ANVS or ALXO?

Summary

How does Annovis Bio compare to Invivyd?

Which has more volatility and risk, IVVD or ANVS?

Which has better valuation & earnings, IVVD or ANVS?

Do analysts prefer IVVD or ANVS?

Does the media favor IVVD or ANVS?

Do institutionals and insiders have more ownership in IVVD or ANVS?

Is IVVD or ANVS more profitable?

Summary

How does Annovis Bio compare to Arcturus Therapeutics?

Does the media prefer ARCT or ANVS?

Is ARCT or ANVS more profitable?

Do analysts prefer ARCT or ANVS?

Which has more risk & volatility, ARCT or ANVS?

Do institutionals and insiders believe in ARCT or ANVS?

Which has stronger earnings & valuation, ARCT or ANVS?

Summary

How does Annovis Bio compare to Alector?

Which has better earnings & valuation, ALEC or ANVS?

Does the media prefer ALEC or ANVS?

Which has more volatility & risk, ALEC or ANVS?

Is ALEC or ANVS more profitable?

Do insiders & institutionals believe in ALEC or ANVS?

Do analysts recommend ALEC or ANVS?

Summary

How does Annovis Bio compare to Emergent Biosolutions?

Do analysts recommend EBS or ANVS?

Which has stronger earnings & valuation, EBS or ANVS?

Does the media refer more to EBS or ANVS?

Which has more volatility and risk, EBS or ANVS?

Is EBS or ANVS more profitable?

Do insiders and institutionals believe in EBS or ANVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools